PhenixFIN Corp
PFX Nasdaq Financials FY2021–FY2025
Last close · Oct 23, 2026
$42.39
0.7%What PhenixFIN Corp does
No business description yet.
- Legal name
- PhenixFIN Corp
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 12, 2025
- Accession · CIK
- 0001213900-25-120913
0001490349
Revenue and margins
PhenixFIN Corp had — of revenue in fiscal 2025.
Net income and earnings per share
From fiscal 2021 to 2025, diluted EPS grew 43.9% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
PhenixFIN Corp returned $3.7M to shareholders in fiscal 2025. The diluted share count fell 1.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably PhenixFIN Corp can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $69.4M | $22.8M | $85.1M | $67.6M | $7.3M |
| Total assets | — | $219M | $240M | $303M | $317M |
| Total liabilities | — | $98.0M | $93.0M | $142M | $156M |
| Shareholders' equity | $144M | $121M | $147M | $160M | $161M |
| Net debt (− = net cash) | — | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | — | ✕ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✕ | ✕ | ✓ | ✕ |
| Return on assets rose | — | — | ✓ | ✕ | ✕ |
| Cash from operations exceeds net income | — | ✕ | ✕ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | — | — | — | — | — |
| Share count didn't rise | — | ✓ | ✓ | ✓ | ✓ |
| Gross margin rose | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — |
| F-score | — / 1 | — / 4 | — / 5 | — / 5 | — / 5 |
| Accruals ratio | — | 10.6% | 20.8% | 0.9% | 23.1% |
| Altman Z'' | — | — | — | — | — |
5 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Interest expense | $5.8M | $5.1M | $5.5M | $6.6M | $10.3M |
| Net income | — | −$6.1M | $26.9M | $18.6M | $4.2M |
| Diluted EPS | $0.48 | −$2.63 | $12.87 | $9.13 | $2.06 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | |||||
| Cash from operations | $95.1M | −$29.3M | −$20.7M | $16.1M | −$67.3M |
| Share buybacks | $8.2M | $17.0M | $1.1M | $2.4M | $0.8M |
| Dividends paid | — | $0.3M | — | $2.6M | $2.9M |
| Dividends and buybacks | $8.2M | $17.2M | $1.1M | $5.0M | $3.7M |
| Balance sheet | |||||
| Cash and short-term investments | $69.4M | $22.8M | $85.1M | $67.6M | $7.3M |
| Total assets | — | $219M | $240M | $303M | $317M |
| Total liabilities | — | $98.0M | $93.0M | $142M | $156M |
| Shareholders' equity | $144M | $121M | $147M | $160M | $161M |
| Returns | |||||
| Return on equity | — | −4.6% | 20.1% | 12.1% | 2.6% |
| Return on assets | — | −2.8% | 11.7% | 6.9% | 1.3% |
| Return on tangible equity | — | −5.1% | 18.3% | 11.6% | 2.6% |
| Growth | |||||
| Net income growth | — | — | — | −30.8% | −77.7% |
| EPS growth | — | −647.9% | — | −29.1% | −77.4% |
| Share count change | — | −13.2% | −10.0% | −2.5% | −1.2% |
| Quality scores | |||||
| Accruals ratio | — | 10.6% | 20.8% | 0.9% | 23.1% |
Source: SEC EDGAR XBRL filings (CIK 0001490349). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.
